{
    "clinical_study": {
        "@rank": "111112", 
        "acronym": "CABA-GCT", 
        "arm_group": {
            "arm_group_label": "Cabazitaxel", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Cabazitaxel is a new generation taxane with a high capacity for blood-brain barrier crossing\n      and limited peripheral neuro-toxicity, two major potential advantages in patients with\n      advanced NSGCTs.\n\n      Cabazitaxel has a broader in vitro spectrum of activity than docetaxel. Taxanes have\n      demonstrated activity in pre-treated GCTs and are now part of standard treatment, but\n      cabazitaxel has not yet been tested in patients with NSGCT."
        }, 
        "brief_title": "A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors", 
        "completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-seminomatous Germ-cell Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms, Germ Cell and Embryonal"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patients aged 15 years or older\n\n          -  Evidence of advanced NSGCT documented either by pathology or by elevated tumor\n             markers (AFP or hCG) and a compatible clinical presentation\n\n          -  Primary site located in either the testis, the retroperitoneum or the mediastinum\n\n          -  Progressive disease after at least 2 lines of chemotherapy for advanced NSGCT (ie,\n             non-stage I)\n\n          -  In case of brain metastases, confirm that patients should be stable / controlled with\n             corticosteroid/anti seizures agents\n\n          -  No other progressive carcinoma within previous the 5 years, except for basal-cell\n             carcinoma of the skin\n\n          -  Life expectancy >/= 3 months\n\n          -  Adequate hematologic function :\n\n          -  Hemoglobin >/= 10.0 g/dL\n\n          -  Absolute neutrophil count >/= 1.5 x 10 ^ 9/L,\n\n          -  Platelet count >/= 100 x 10 ^ 9/L,\n\n          -  Adequate organ function\n\n          -  Serum creatinine < 1.5 x ULN. If serum creatinine 1.0 - 1.5 x ULN, creatinine\n             clearance calculated (or measured) according to CKD-EPI formula (see Appendix B) > 60\n             mL/min\n\n          -  AST/SGOT and ALT/SGPT </= 1.5 x ULN\n\n          -  Bilirubin </= 1.5 x ULN\n\n          -  Information delivered to patient and informed consent form signed by the patient or\n             his legal representative\n\n          -  Patient affiliated to a social security system or beneficiary of the same\n\n        Exclusion Criteria:\n\n          -  Patients receiving an investigational drug within 4 weeks prior to enrolment\n\n          -  Previous radiotherapy within 4 weeks prior to enrolment\n\n          -  Serious uncontrolled concurrent medical illness\n\n          -  History of severe hypersensitivity reaction (>/= grade 3) to polysorbate 80\n             containing drugs or to other taxanes\n\n          -  Concurrent or planned treatment with strong inhibitors or strong inducers of\n             cytochrome P450 3A4/5 (see Appendix A). A one week wash-out period is necessary for\n             patients who are already on these treatments.\n\n          -  Patient with reproductive potential not implementing accepted and effective method of\n             contraception for up to 6 months after the last dose of cabazitaxel.\n\n          -  Active Grade >/= 3 peripheral neuropathy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115165", 
            "org_study_id": "2013-000286-36", 
            "secondary_id": "2012/1950"
        }, 
        "intervention": {
            "arm_group_label": "Cabazitaxel", 
            "description": "On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m\u00b2, administered by IV route in 1 hour", 
            "intervention_name": "Cabazitaxel", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "email": "karim.fizazi@gustaveroussy.fr", 
                "last_name": "Karim FIZAZI, MD-PhD", 
                "phone": "0142116264", 
                "phone_ext": "+33"
            }, 
            "contact_backup": {
                "email": "geraldine.martineau@gustaveroussy.fr", 
                "last_name": "G\u00e9raldine MARTINEAU, MD", 
                "phone": "01422115607", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Gustave Roussy Cancer Campus Grand Paris"
            }, 
            "investigator": {
                "last_name": "Karim FIZAZI, MD-PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors", 
        "overall_contact": {
            "email": "karim.fizazi@gustaveroussy.fr", 
            "last_name": "Karim FIZAZI, MD-PhD", 
            "phone": "0142116264", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "geraldine.martineau@gustaveroussy.fr", 
            "last_name": "G\u00e9raldine MARTINEAU, MD", 
            "phone": "0142115607", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Karim FIZAZI, MD-PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the favorable response rate of cabazitaxel treatment in patients with highly-pretreated nonseminomatous germ-cell tumors (NSGCT)", 
            "measure": "Favorable response", 
            "safety_issue": "No", 
            "time_frame": "Assessed every 6 weeks from start of treatment up to 72 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "MRI of the brain every 6 weeks only in case of brain metastases detected at baseline and for all patients at the end of the study.\nEvaluation will be made using RECIST V1.1", 
                "measure": "Response rate on brain metastases", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 6 weeks after treatment start up to 72 months"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 6 weeks from treatment start to progression up to 72 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Assessed every 3 weeks after treatment start up to 72 months"
            }
        ], 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}